Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.08 or 1.14% from the prior close of $7.02. The stock opened at $7.02 and touched ...

Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ: SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...